- Previous Close
12.28 - Open
12.43 - Bid 13.18 x --
- Ask 13.20 x --
- Day's Range
12.41 - 13.31 - 52 Week Range
10.90 - 24.25 - Volume
705,357 - Avg. Volume
568,658 - Market Cap (intraday)
1.717B - Beta (5Y Monthly) 2.17
- PE Ratio (TTM)
12.94 - EPS (TTM)
1.02 - Earnings Date Jan 29, 2025 - Feb 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.00
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
www.neurenpharma.comRecent News: NEU.AX
View MorePerformance Overview: NEU.AX
Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEU.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEU.AX
View MoreValuation Measures
Market Cap
1.60B
Enterprise Value
1.25B
Trailing P/E
12.08
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.18
Price/Book (mrq)
4.51
Enterprise Value/Revenue
5.51
Enterprise Value/EBITDA
7.19
Financial Highlights
Profitability and Income Statement
Profit Margin
60.66%
Return on Assets (ttm)
59.56%
Return on Equity (ttm)
75.51%
Revenue (ttm)
193.34M
Net Income Avi to Common (ttm)
117.29M
Diluted EPS (ttm)
1.02
Balance Sheet and Cash Flow
Total Cash (mrq)
213.17M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
98.45M